title: Cancer risk with topical pimecrolimus and tacrolimus.
abstract: (1) Disturbing reports of cancers linked to topical application of tacrolimus or pimecrolimus have been published. Some involved children. Animal studies had already shown a dose-dependent increase in the incidence of lymphoma in mice and monkeys. (2) In practice, it is better to avoid topical application of these immunosuppressants, which have a negative risk-benefit balance.
mesh_terms: D000287:Administration, Topical; D000328:Adult; D002648:Child; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000139:chemically induced*; D016559:Tacrolimus / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus